MX2009007742A - Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada. - Google Patents

Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.

Info

Publication number
MX2009007742A
MX2009007742A MX2009007742A MX2009007742A MX2009007742A MX 2009007742 A MX2009007742 A MX 2009007742A MX 2009007742 A MX2009007742 A MX 2009007742A MX 2009007742 A MX2009007742 A MX 2009007742A MX 2009007742 A MX2009007742 A MX 2009007742A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
oral bioavailability
poorly water
improved oral
soluble drugs
Prior art date
Application number
MX2009007742A
Other languages
English (en)
Inventor
Dinesh Shenoy
Robert Lee
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of MX2009007742A publication Critical patent/MX2009007742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las formulaciones farmacéuticas descritas comprenden una composición farmacéutica multi-fásica que comprende un ingrediente farmacéuticamente activo, en donde el ingrediente farmacéuticamente activo está en un estado de partícula, un estado solubilizado, o un estado de partícula y en un estado solubilizado; un solvente; in líquido no miscible; un estabilizador; y agua, en donde la formulación farmacéutica es una forma de dosificación oral. Esas formulaciones farmacéuticas son capaces de reducir la variabilidad con alimentación/en ayunas y mejorar la biodisponibilidad oral a la cual un número de ingredientes farmacéuticamente activos son susceptibles. Las formulaciones farmacéuticas de la invención, por consiguiente son bioequivalentes en los estados de alimentación y en ayunas y mejorados en biodisponibilidad oral.
MX2009007742A 2007-01-22 2008-01-22 Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada. MX2009007742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88147007P 2007-01-22 2007-01-22
PCT/US2008/051639 WO2008091855A1 (en) 2007-01-22 2008-01-22 Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability

Publications (1)

Publication Number Publication Date
MX2009007742A true MX2009007742A (es) 2009-07-27

Family

ID=39644850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007742A MX2009007742A (es) 2007-01-22 2008-01-22 Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.

Country Status (10)

Country Link
US (1) US20100143420A1 (es)
EP (1) EP2051702A1 (es)
JP (1) JP2010516704A (es)
CN (1) CN101674813A (es)
AU (1) AU2008207986A1 (es)
BR (1) BRPI0806876A2 (es)
CA (1) CA2675766A1 (es)
MX (1) MX2009007742A (es)
RU (1) RU2009131749A (es)
WO (1) WO2008091855A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090131386A1 (en) 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
CN102335207A (zh) * 2010-07-26 2012-02-01 重庆市力扬医药开发有限公司 含硅酸铝镁和挥发油的组合物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
CN103385215A (zh) * 2012-05-07 2013-11-13 浙江中医药大学 一种高嘌呤饲料喂养致生活性高血压动物模型的制备方法
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
CA2942186C (en) 2014-06-18 2023-06-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising non-ionic surfactants
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
CA3165081A1 (en) * 2020-01-24 2021-07-29 Toru Yasuzawa External preparation containing rapamycin
CN112121022A (zh) * 2020-09-25 2020-12-25 迪沙药业集团有限公司 一种非诺贝特片组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US20050129777A1 (en) * 2000-12-22 2005-06-16 Hassan Emadeldin M. Elemental nanoparticles of substantially water insoluble materials
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
BRPI0806876A2 (pt) 2014-04-29
AU2008207986A1 (en) 2008-07-31
CN101674813A (zh) 2010-03-17
CA2675766A1 (en) 2008-07-31
EP2051702A1 (en) 2009-04-29
WO2008091855A1 (en) 2008-07-31
US20100143420A1 (en) 2010-06-10
RU2009131749A (ru) 2011-02-27
JP2010516704A (ja) 2010-05-20

Similar Documents

Publication Publication Date Title
MX2009007742A (es) Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.
WO2009033131A3 (en) Multi-phasic, nano-structured compositions containing a combination of a fibrate and a statin
WO2004105694A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2007047948A3 (en) Intranasal administration of rapid acting insulin
WO2011014850A3 (en) Topical eutectic-based formulations
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
MY160652A (en) Pharmaceutical composition for oral administration
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
WO2007011958A3 (en) Intraoral dosage forms of glucagon
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
WO2011035343A3 (en) Phentermine liquid dosage form
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
BR112023003572A2 (pt) Formulação oral sólida de utidelona